Detalhe da pesquisa
1.
Turning liabilities into opportunities: Off-target based drug repurposing in cancer.
Semin Cancer Biol
; 68: 209-229, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32044472
2.
Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells.
Mol Cell Proteomics
; 17(12): 2434-2447, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30217950
3.
Polypharmacology-based ceritinib repurposing using integrated functional proteomics.
Nat Chem Biol
; 13(12): 1222-1231, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28991240
4.
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells.
Proc Natl Acad Sci U S A
; 110(30): 12414-9, 2013 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-23836654
5.
Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.
Cell Chem Biol
; 31(2): 284-297.e10, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37848034
6.
IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells.
Sci Signal
; 15(747): eabj5879, 2022 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35973030
7.
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Exp Hematol
; 36(10): 1244-53, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18619723
8.
Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia.
Sci Rep
; 9(1): 606, 2019 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30679640
9.
Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model.
FEBS Open Bio
; 9(10): 1689-1704, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31314158
10.
Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.
Cell Chem Biol
; 26(9): 1240-1252.e11, 2019 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257184
11.
Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.
Mol Oncol
; 12(1): 74-88, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29112787
12.
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
ACS Chem Biol
; 12(7): 1883-1892, 2017 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28557434
13.
Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
ACS Chem Biol
; 10(12): 2680-6, 2015 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26390342
14.
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.
ACS Chem Biol
; 9(2): 353-8, 2014 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24215125
15.
A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.
PLoS One
; 8(10): e77155, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24130846
16.
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Blood
; 110(12): 4055-63, 2007 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17720881
17.
The dynamic structure of jadomycin B and the amino acid incorporation step of its biosynthesis.
J Am Chem Soc
; 126(14): 4496-7, 2004 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-15070349
18.
The oxidative ring cleavage in jadomycin biosynthesis: a multistep oxygenation cascade in a biosynthetic black box.
Chembiochem
; 6(5): 838-45, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15776503